Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06075745 · ClinicalTrials.gov registry record · Phase 2

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

A Phase 2 study of Liver Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
Phase 2
Development phase
416
Enrollment target
18
Study locations

NCT06075745 is a Phase 2 study of Liver Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 416 participants, below the 5,436-participant average among 19 other Liver Transplant trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06075745, a Phase 2 study of Liver Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
Phase 2
Development phase
416 participants
Enrollment target
18
Study locations

Study Summary

This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (LTxRs). A protocol-mandated preemptive therapy (PET) will be used for CMV disease prevention in D+R- LTxRs.

Conditions Studied

Liver Transplant

Interventions

  • DRUG CMV-MVA Triplex
  • DRUG Placebo for CMV-MVA Triplex

Study Locations (18)

California

  • University of California, San Diego School of Medicine - La Jolla
  • Stanford University - Redwood City
  • University of California, San Francisco - San Francisco

Pennsylvania

  • University of Pennsylvania School of Medicine - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Alabama

  • University of Alabama at Birmingham, School of Medicine - Birmingham

Florida

  • University of Miami, Jackson Memorial Hospital - Miami

Georgia

  • Emory University Hospital - Atlanta

Illinois

  • Northwestern University, Feinberg School of Medicine - Chicago

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Michigan

  • University of Michigan Medical Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 416 participants
Start Date 2024-03-05
Est. Completion 2028-02-28
Phase Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06075745

The ClinicalTrials.gov registry entry for NCT06075745 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,436-participant average among 19 other Liver Transplant trials with a reported enrollment target (92% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 2 interventions - of which CMV-MVA Triplex is the first listed.

NCT06075745 reports 18 study locations spanning 15 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.

Frequently Asked Questions

What is clinical trial NCT06075745 about?

NCT06075745 is a clinical study titled "Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates". This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-tr...

What is the current status of trial NCT06075745?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2024-03-05. Estimated completion is 2028-02-28.

What conditions does trial NCT06075745 study?

This clinical trial studies the following conditions: Liver Transplant.

What interventions are being tested in trial NCT06075745?

The interventions under investigation include: CMV-MVA Triplex (DRUG), Placebo for CMV-MVA Triplex (DRUG).

Who is sponsoring clinical trial NCT06075745?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06075745 being conducted?

This trial has 18 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Transplant

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.